eligibility_summary
Eligible: adults (≥18) with head/neck salivary ACC (any stage) without recurrent/metastatic/incurable disease, planned definitive surgery, ECOG 0–1, measurable primary ≥1×1 cm, medically fit for percutaneous/surgical procedures, labs ≤7 days: platelets ≥50k, PT/INR <2, aPTT <1.5×ULN, negative pregnancy test if applicable, consent. FNA suggestive of ACC acceptable. Exclude: other trials, uncontrolled illness, pregnancy, uncorrectable bleeding/coagulopathy, anticoagulation by PI review.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: an implantable microdevice (IMD) that locally releases up to 20 anticancer agents into ACC/salivary tumors for 3–5 days pre-resection to measure in situ response. Agents may include: lenvatinib (small-molecule multi-TKI inhibiting VEGFR/FGFR/PDGFR/RET/KIT, anti-angiogenic), axitinib (small-molecule VEGFR TKI, anti-angiogenic), all-trans retinoic acid/ATRA (retinoid, RAR agonist driving differentiation/apoptosis), venetoclax (small-molecule BCL-2 inhibitor, pro-apoptotic), pembrolizumab (anti–PD-1 monoclonal antibody, immune checkpoint blockade), cisplatin/carboplatin (platinum DNA crosslinkers, cytotoxic chemo), vinorelbine (vinca alkaloid, microtubule inhibitor). Targeted cells/pathways: tumor endothelial/angiogenic signaling (VEGF axis), tumor cell survival/apoptosis (BCL-2), immune evasion (PD-1/PD-L1), cell differentiation (RAR), DNA damage response, and mitotic spindle/microtubules in tumor and microenvironment.